Previous 10 | Next 10 |
Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipeline Research highlighting novel reprogramming technologies designed to overcome barriers to successful adoptive cell therapy in solid tumors present...
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in ...
Gainers: Gaia (GAIA) +14%. AST SpaceMobile (ASTS) +11%. Harmonic (HLIT) +10%. Cardlytics (CDLX) +10%. Monolithic Power Systems (MPWR) +7%. Losers: EverQuote (EVER) -15%. Varonis Systems (VRNS) -10%. Shattuck Labs (STTK) -9%. SoundHound ...
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that two abstracts have been accepted for poster presentations at th...
Gainers: Spruce Biosciences (SPRB) +7%. ThredUp (TDUP) +7%. Cellectis (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats (SEAT) -6%. Y-mAbs Therapeutic...
Lyell Immunopharma press release (NASDAQ:LYEL): Q4 net loss of $83.70M Revenue of $2.31M (-18.1% Y/Y). For further details see: Lyell Immunopharma reports Q4 results
Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipeline Clinical development commencing for two programs that incorporate Lyell’s novel reprogramming technologies SOUTH SAN FRANCISCO,...
Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the ma...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A ...
News, Short Squeeze, Breakout and More Instantly...
Lyell Immunopharma Inc. Company Name:
LYEL Stock Symbol:
NASDAQ Market:
Lyell Immunopharma Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 56.4% to $0.21 on volume of 112,154,340 shares Rivian Automotive Inc. (RIVN) rose 31.8% to $15.76 on volume of 70,797,368 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 48.3% to $...
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 10 6 CAR T cells) First demonstration that CAR T cells enhanced with anti-exhaus...